Loss widens sharply. Prelude Therapeutics Inc (NASDAQ: PRLD) reported a loss of $1.29 per share for Q4 2025, wider than the expected loss of $0.18 per share. The biotech posted a net loss of $99.5 million and operating loss of $104.6 million for the quarter. The $1.11 per-share gap represents a 616.7% wider loss than consensus anticipated, a significant deterioration from Q3 2025 when the company posted a loss of just $0.26 per share that beat estimates by 26.8%.
Revenue jumps sequentially. The company generated revenue of $12.1 million for the quarter, up 86.5% from $6.5 million in Q3 2025. The prior two quarters of fiscal 2025 saw zero revenue, making Q4’s $12.1 million a notable inflection. With a market capitalization of $194.3 million and shares trading at $3.23, the stock showed minimal movement on 285,422 shares of volume following the before-market-open release.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.